Chronic Lymphocytic Leukemia New Protocol: Acalabrutinib + Venetoclax for Fixed Duration with/without Obinutuzumab Ulas D. Bayraktar, MD 2025-02-07
Colorectal Cancer New Protocol: Ipilimumab + Nivolumab for MSI-H Colorectal Cancer Ulas D. Bayraktar, MD 2025-01-31
GastroEsophageal Cancer New Reference: Periop FLOT in Esophageal Cancer Ulas D. Bayraktar, MD 2025-01-24
Breast Cancer New Reference: Trastuzumab Emtansine in HER2-Positive Breast Cancer with Residual Disease Ulas D. Bayraktar, MD 2025-01-24
Breast Cancer New Drug: Datopotamab Deruxtecan for HR+, her2 Neg Breast Cancer Ulas D. Bayraktar, MD 2025-01-20
Mantle cell lymphoma New Protocol: Acalabrutinib with R-Bendamustine for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2025-01-19
Non-Small Cell Lung Cancer Pancreatic Cancer New Drug: Zenocutuzumab for advanced NRG1 fusion positive NSCLC and Pancreatic Cancer Ulas D. Bayraktar, MD 2024-12-06
GastroEsophageal Cancer New Drug: Zolbetuximab with FOLFOX for Gastric and GE Junction Cancer Ulas D. Bayraktar, MD 2024-11-11
Non-Small Cell Lung Cancer New Indication: Osimertinib after Chemoradiotherapy in NSCLC Ulas D. Bayraktar, MD 2024-09-30
Non-Small Cell Lung Cancer New Drug: Lazertinib for EGFR mutated NSCLC Ulas D. Bayraktar, MD 2024-08-27
